Target intelligence / Profile preview

Staphylococcal enterotoxin B (SEB) (SEB)

Target
SEB
Molecular classification
Superantigen, Bacterial toxin, Exotoxin, Pyrogenic toxin
01

Overview

Staphylococcal enterotoxin B (SEB) is a potent exotoxin and superantigen produced by the bacterium Staphylococcus aureus. It is a primary cause of food poisoning and is also responsible for non-menstrual toxic shock syndrome (TSS) [1, 2]. SEB functions by bypassing normal antigen processing and directly cross-linking major histocompatibility complex (MHC) class II molecules on antigen-presenting cells with the V-beta region of T-cell receptors [7, 11]. This interaction leads to the massive, non-specific activation of up to 20% of the body's T-cells, triggering a 'cytokine storm' characterized by the overproduction of pro-inflammatory mediators like TNF-alpha and interferon-gamma [14, 15]. Due to its extreme stability and high toxicity via inhalation, SEB is classified as a Category B select agent and has been historically studied as a biological weapon [6, 9]. Therapeutic strategies focus on neutralizing monoclonal antibodies (e.g., Hm0487), toxoid vaccines (such as STEBVax), and immunosuppressive agents to mitigate the systemic inflammatory response [8, 13, 14].

Other names
Enterotoxin type BentBStaphylococcal enterotoxin type B
02

Mechanism of action

Neutralization of the toxin to prevent MHC-II and TCR cross-linking; downregulation of the inflammatory cytokine response.

03

Biological functions

Immune response activationCytokine releaseT-cell proliferationMHC class II bindingT-cell receptor binding
04

Disease associations

InfectionFood poisoningToxic shock syndromeSepsisInflammationAutoimmune disease
05

Safety considerations

High toxicity (low LD50/ED50)Risk of lethal cytokine stormPotential for aerosolization (bioweapon agent)Environmental and heat stability
06

Interacting drugs

Hm0487

6 more in the full profile.

07

Biomarkers

Tumor necrosis factor-alpha (TNF-alpha)Interferon-gamma (IFN-gamma)Interleukin-2 (IL-2)Interleukin-6 (IL-6)SEB-specific antibody titersT-cell activation markers (e.g., CD69, CD25)

Beyond the preview

Go deeper on Staphylococcal enterotoxin B (SEB) (SEB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcal enterotoxin B (SEB) (SEB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call